Podcasts about ppar

New therapeutic agents for second-line treatment are raising the bar for primary biliary cholangitis (PBC) management. Listen now to learn how to incorporate these new agents into clinical practice and how these agents will impact attainment of treatment goals.Topics covered include:Available agents for second-line treatment of PBC An overview of clinical trial data supporting second-line agents:Obeticholic acid (OCA)BezafibrateElafibranorSeladelparThis episode is the second of 3 recap podcasts, featuring audio from our live satellite symposium, Raising the Bar: Innovations in PBC Care. For the full on-demand webcast of this satellite symposium, and to download the accompanying slides, visit the program page for this episode: https://bit.ly/48MEc3rPresenters:Christopher L. Bowlus, MDLena Valente Professor and ChiefDivision of Gastroenterology and HepatologySchool of MedicineUniversity of California DavisSacramento, CaliforniaAparna Goel, MDClinical Associate Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaAliya F. Gulamhusein, MD, MPH, FRCPCProfessorship in PSC ResearchClinician Investigator, Toronto General HospitalAssistant Professor, University of TorontoDivision of Gastroenterology and HepatologyUniversity Health NetworkToronto, CanadaGet access to all of our new episodes by subscribing to the Decera Clinical Education Medical Specialties Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Historically, key symptoms of primary biliary cholangitis (PBC), such as pruritus and fatigue, have been understudied and undertreated. Listen now to learn how symptom management should be considered independently of PBC management, and how new therapeutic agents can help.Topics covered include:Mechanisms of pruritus and fatigue in PBCNonpharmacologic treatment optionsAn overview of clinical trial data supporting second-line agents for symptom management:BezafibrateElafibranorSeladelparInvestigational agents:VolixibatLinerixibatSetanaxibThis episode is the third of 3 recap podcasts, featuring audio from our live satellite symposium, Raising the Bar: Innovations in PBC Care. For the full on-demand webcast of this satellite symposium, and to download the accompanying slides, visit the program page for this episode:https://bit.ly/44ZJ5osPresenters:Christopher L. Bowlus, MDLena Valente Professor and ChiefDivision of Gastroenterology and HepatologySchool of MedicineUniversity of California DavisSacramento, CaliforniaAparna Goel, MDClinical Associate Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaAliya F. Gulamhusein, MD, MPH, FRCPCProfessorship in PSC ResearchClinician Investigator, Toronto General HospitalAssistant Professor, University of TorontoDivision of Gastroenterology and HepatologyUniversity Health NetworkToronto, CanadaGet access to all of our new episodes by subscribing to the Decera Clinical Education Medical Specialties Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Advancements in our understanding of primary biliary cholangitis (PBC) and new therapeutic agents have reshaped the care landscape of PBC. Listen now to learn how these developments are helping to redefine and elevate treatment goals. Topics covered include:How and when to assess treatment responseRisk factors in PBCBiochemical treatment response and fibrosis stage as predictors of transplant-free survivalDynamics of liver stiffness measurements and clinical outcomes in PBC The importance of bilirubin and alkaline phosphatase normalizationThis episode is the first of 3 recap podcasts, featuring audio from our live satellite symposium, Raising the Bar: Innovations in PBC Care. For the full on-demand webcast of this satellite symposium, and to download the accompanying slides, visit the program page for this episode: https://bit.ly/44ZJ5osPresenters:Christopher L. Bowlus, MDLena Valente Professor and ChiefDivision of Gastroenterology and HepatologySchool of MedicineUniversity of California DavisSacramento, CaliforniaAparna Goel, MDClinical Associate Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaAliya F. Gulamhusein, MD, MPH, FRCPCProfessorship in PSC ResearchClinician Investigator, Toronto General HospitalAssistant Professor, University of TorontoDivision of Gastroenterology and HepatologyUniversity Health NetworkToronto, CanadaGet access to all of our new episodes by subscribing to the Decera Clinical Education Medical Specialties Podcast on Apple Podcasts, YouTube Music, or Spotify.   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Aastaid räpparina muusikat avaldanud Metsakutsu ehk Rainer Olbri kinnitas mullu kanda ettevõttes Bolt, saades selle loovjuhiks. Oma pikaaegse partneri Ülliga abiellus Olbri viie aasta eest ning nende peres kasvab laste asemel neli koera. Räppari mitmekesist elu kaunistavad ka omapärased hobid, sealhulgas tossude kogumine.Külas on Metsakutsu ehk Rainer Olbri ja saatejuht on Maiken Tiits.

In this episode, Ben Azadi reveals how most people are using olive oil completely wrong — and how drinking high-quality extra virgin olive oil at the right time can melt belly fat, lower cortisol, reduce inflammation, and boost metabolic health in as little as one day. Ben explains the science behind olive oil's fat-burning power, including how it activates PPAR-alpha, improves GLP-1, stabilizes blood sugar, lowers insulin, and shuts down inflammation at the cellular level. He also breaks down how polyphenols like oleocanthal help regulate the HPA axis, improve sleep, boost autophagy, and enhance brain clarity. You'll learn the biggest mistakes people make with olive oil, why most store-bought oils are fake or oxidized, and why early-harvest, cold-pressed, high-polyphenol oil is essential. Ben shares his exact olive oil protocol, including: The morning fasted olive oil shot to lower cortisol How to pair olive oil with high-polyphenol foods When to take olive oil before meals for smaller glucose spikes How to use it at night or during 3 a.m. wake-ups His one-day “fat loss reset” using olive oil He also discusses why he personally uses the Fresh Pressed Olive Oil Club and offers his audience an exclusive “buy 2, get the 3rd free” link: http://benazadi.com/oliveoil  FREE GUIDE: 7-Day Fat-Burning Guide - https://bit.ly/4pnYoiB  This episode is a practical, science-backed guide for using one of the world's oldest superfoods as a metabolic medicine to burn fat, balance hormones, reduce stress, and improve longevity.

Stuart C. Gordon, MD - Data-Driven Decision-Making in Primary Biliary Cholangitis: Evaluating the Expanding Evidence Base for PPAR Agonists

Stuart C. Gordon, MD - Data-Driven Decision-Making in Primary Biliary Cholangitis: Evaluating the Expanding Evidence Base for PPAR Agonists

Tune in to listen as expert faculty, Dr Christopher L. Bowlus and Dr Sonal Kumar, discuss recent developments in treating primary biliary cholangitis (PBC) with new and emerging agents, as well as strategies to integrate these advances into clinical practice.Topics covered include: Methods of Assessing PBC Disease ProgressionNewer Agents for Second-line Treatment of PBCPrioritizing Symptom Management and Quality of Life With PBC TreatmentPresenters:Christopher L. Bowlus, MDLena Valenta Professor and ChiefDivision of Gastroenterology and HepatologySchool of Medicine University of California Davis Sacramento, CaliforniaSonal Kumar, MD, MPHAssistant Professor of MedicineDivision of Gastroenterology and HepatologyWeill Cornell Medical CollegeNew York, New YorkLink to full program: https://bit.ly/43nHx6UGet access to all of our new podcasts by subscribing to the CCO Medical Specialties Podcast on Apple Podcasts, Google Podcasts, or Spotify.     Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Världens regeringar utlovar stora satsningar på försvar och infrastruktur, samtidigt som man lovar att sänka skatterna. Hur ska då detta finansieras, och när blir statsskulden ett problem för börsen? I dagens Börslunch gästar Therese Persson, förvaltare på Lannebo och Roger Josefsson från Brummer & Partners. Programmet leds av Elin Wiker och Jesper Norberg.

Sageli arvatakse, et räpparid ja artistid on tugevad ja kartmatud, kuid tegelikult on nad samamoodi inimesed oma mõtete ja kahtlustega. Räppar Cool D tunnistab, et ta on sageli inimene, kes analüüsib asju üle. Kroonika taskuhäälingus „Tähetund“ räägib ta lähemalt oma sisemaailmast, kaksikute kasvatamisest ja pikaajalisest suhtest. Ta on ajaga õppinud, et ka laste kasvatamisel tuleb improviseerida. Seega tõdeb räppar, et kui lapsevanem suudab pakkuda lapsele teistsuguse ja põneva lahenduse, kulgeb olukord tihtilugu rahulikumalt. Külas on Priit Kolsar ja saatejuht on Kerli Kivistu.

Stort demenstest i podden. Louise har dessvärre ålderskris och varken Julia eller Tradera hjälper till. Men glöm aldrig orden "plånbok, tång, sax, magnet, bord... "Tack My Helsinki för veckans poddspons! (Myhelsinki.fi)

Send us a textThis conversation is the fourth and final segment of SurfingMASH's April discussion of drug development in memory of Stephen A. Harrison. In addition to co-hosts Jörn Schattenberg, Louise Campbell and Roger Green, panelists include hepatologist and key opinion leader Sven Francque. The discussion focuses on PPARs, genetic medicines, and other emerging drug classes while considering the idea that drug therapies can have an impact on the liver independent of their effect on fibrosis regression. It begins with Sven  discussing his experience as a lead investigator in clinical trials for the pan-PPAR agonist lanifibranor, whose Phase 3 trial is now fully recruited. Sven states that in addition to fibrosis regression, lanifibranor is likely to exhibit other pleiotropic effects, and notes that vascular changes start early in the fibrotic progression process. After Sven elaborates on these effects, Louise asks about the SCD-1 agent Aramchol. This leads to a discussion about the idea that over time, therapy will probably come to incorporate two separate modes of action, with one to treat the metabolic dysfunction and the other to treat specific effects in the liver or, as Jörn puts it, "combining weight-neutral and weight-reducing drugs." This evolves into a discussion of what Louise terms "personal-centric" medicine, or what patient advocate Mike Betel has previously described on SurfingMASH as "tailored medicine."The rest of the conversation predominantly lists other classes of drugs, "safe" mitochondrial uncouplers, genetic medicines, and others. Roger inquires about the FASN inhibitors, which are entering Phase 3 clinical trials. Jörn says that the data appears positive and unique. That said, he and Sven agree we need more data.Louise sounds the closing note for this roundtable by discussing our co-founder, Stephen Harrison, and the energy and enthusiasm he brought to the entire drug development process. The group agrees that Stephen's impact continues to be felt through the MASLD community, even as he is missed by us all.

Send us a text00:00 - Surf's Up, Season 6 Episode 8The conversation addresses three issues that are distinct, yet each is pivotal to the future of MASLD and MASH therapies. The first, from the Global Think-Tank on Steatotic Liver Disease, considers how personal and digital approaches can be combined to form the most effective strategy for patient management. In the second, Global Liver Institute President and CEO Larry Holden joins Roger Green to discuss the new challenges in Washington stemming from the Trump Administration and RFK Jr. The final section is the conclusion of our recent drug development roundtable, examining drug classes we did not previously discuss, along with a thought on where combination therapy is likely to lead. 00:04:57 - Global Think-Tank on SLD Roundtable, Part 2Behavior consultant Dr. Kristina Curtis joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss issues related to patient-centered care. This discussion focuses on the elements of successful behavior change and the importance of real-time, actionable feedback. The group discusses the interplay of diagnostic test feedback, real-time personal exchanges and AI-based algorithms in what Kristina terms a "hybrid therapy."00:18:39 - Newsmaker: Larry HoldenGLI President and CEO Larry Holden addresses two issues related to current goings-on in Washington. First, he acknowledges that we are in for "dark times" under the current administration, and describes some of the decisions and challenges we face. Second, he suggests what individuals and organizations can do to create the best possible situation -- and even some "wins" -- for people living with liver disease. These suggestions reflect his experiences during a 30-year career on Capitol Hill, prior to his joining GLI.00:46:15 - Drug Development Roundtable, Part 4Sven Francque joins Jörn, Louise and Roger to share an up-to-date look at drug development. This discussion focuses on PPARs, genetic medicines, and other emerging drug classes. Sven uses the example of the pan-PPAR lanifibranor to explore the idea that drug therapies can have an impact on the liver independent of their effect on fibrosis regression. The group proceeds to discuss other emerging drugs in development and their modes of action. One theme: over time, we may see prescribers consider using different therapies to address metabolic vs. liver-specific effects, often in combination.01:00:47 - Business ReportThanks to our listeners, Jörn's vacation, Welcome Regeneron

Un equipo internacional de científicos liderados desde Aragón ha identificado el papel clave de la proteína PPAR-delta como un sensor metabólico que permite a las células tumorales del cáncer de páncreas adaptarse a la escasez de oxígeno y nutrientes, condiciones habituales en el entorno del tumor. Esta proteína activa un programa que reconfigura el metabolismo celular y favorece un comportamiento más invasivo y metastásico. El estudio está liderado por Patricia Sancho y Beatriz Parejo (grupo 'Metabolismo y Células Madre Tumorales' del IIS Aragón). Ambas explican desde la nueva Unidad de Investigación Traslacional del Hospital Miguel Servet cómo interferir en la capacidad invasiva de las células cancerosas para frenar la formación de metástasis

In this podcast, expert faculty, Dr Stuart Gordon and Dr Nancy Reau discuss an illustrative patient case to demonstrate how they individualize primary biliary cholangitis (PBC) therapy for patients ​with cirrhosis. Topics covered include:AASLD guideline recommendations for second-line therapy for PBCConsiderations when using newer agents for second-line treatment of PBC in patients with cirrhosis: elafibranor and seladelparPresenters:Stuart C. Gordon, MD Professor of MedicineWayne State University School of MedicineDirector, Division of HepatologyHenry Ford HealthDetroit, MichiganNancy Reau, MD Professor of MedicineRichard B. Capps Chair of HepatologyChief, Section of HepatologyAssociate Director, Solid Organ TransplantationRush University Medical CenterChicago, IllinoisTo learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.Supported by educational grants from Gilead Sciences, Inc. and Ipsen Biopharmaceuticals, Inc

In this podcast, expert faculty, Dr Stuart Gordon and Dr Nancy Reau, use an illustrative patient case to explore the roles of ALP and other biochemical markers in PBC management, and explain what to expect from treatment. Topics covered include: How baseline ALP can affect ALP normalization after second-line treatment with elafibranor and seladelparPotential outcomes if ALP normalization cannot be achievedThe importance of managing fatigue, pruritus, and sleep disturbances independently of the biochemical responsePresenters:Stuart C. Gordon, MDProfessor of MedicineWayne State University School of MedicineDirector, Division of HepatologyHenry Ford HealthDetroit, MichiganNancy Reau, MDProfessor of MedicineRichard B. Capps Chair of HepatologyChief, Section of HepatologyAssociate Director, Solid Organ TransplantationRush University Medical CenterChicago, IllinoisTo learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management. Supported by educational grants from Gilead Sciences, Inc. and Ipsen Biopharmaceuticals, Inc

In this podcast, Sonal Kumar, MD, MPH, meets with patient advocate Maria Morais to discuss actionable steps that healthcare providers can incorporate into the care of people with primary biliary cholangitis (PBC). Listen as they discuss:The chronic nature of PBCGoing beyond biochemical markers to assess and address symptoms such as fatigue and pruritusThe importance of referral to patient support groupsPresenters:Sonal Kumar, MD, MPHAssistant Professor of MedicineDirector, General Gastroenterology and HepatologyWeill Cornell Medical CollegeNew York, New YorkMaria G. Morais, RNVP Patient AdvocacyCanadian PBC SocietyToronto, CanadaTo learn more, see the programHear Me: Patient Perspectives on PBC

Räppar, sisulooja ja ettevõtja Säm on tuntud oma hittlugude poolest, mis kõnetavad eriti tugevalt nooremat generatsiooni. Tema sõnul on parim inspiratsiooniallikas elu ise ja eriti uued kogemused. Mõnikord piisabki sellest, et sõita argipäevaõhtul kodukohast mõnda suvalisse suunda või lihtsalt vaadata ümbritsevat teadlikumalt ja avatud pilguga. Säm peab end heaks kuulajaks – inimeseks, kellega on lihtne leida ühist keelt. Empaatiavõime pärineb tema sõnul emalt, ettevõtlikkus isalt. Kuna ta on suuresti üles kasvanud naiste keskel, peab ta end isegi natuke feminiinseks. Külas on Sam Schmidt ja saatejuht on Kerli Kivistu.

Här kan du lyssna på en AI-genererad uppläsning av följande artikel: Hindren som satt käppar i hjulet för Teslastrejken: ”Inte så effektiv som den kunde blivit”

How do you decide when to move from first-line to second-line treatment for primary biliary cholangitis (PBC)? In this podcast, listen as experts Alan Bonder, MD, AGAF, and Aparna Goel, MD, discuss this question and more, including:How and when to measure treatment responseEvidence-based goals of therapyConsiderations for second-line treatmentNew agents for second-line treatment: PPAR agonistsPresenters:Alan Bonder, MD, AGAFAssociate Professor of MedicineMedical Director of Liver TransplantDepartment of GastroenterologyBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsAparna Goel, MDAssociate Clinical Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaContent based on an online CME program supported by independent educational grants from Gilead Sciences, Inc., and Ipsen Biopharmaceuticals, Inc​.To learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.Supported by educational grants from Gilead Sciences, Inc. and Ipsen Biopharmaceuticals, Inc

In this podcast, listen as experts Alan Bonder, MD, AGAF, and Aparna Goel, MD, discuss how they assess the symptoms of primary biliary cholangitis (PBC) and explore how new therapeutic agents may help alleviate symptom burden. Topics include:Strategies and tools for assessing pruritusNonpharmacologic and pharmacologic management of pruritusSecond-line agents and their impact on pruritusInvestigational treatments for pruritusPresenters:Alan Bonder, MD, AGAFAssociate Professor of MedicineMedical Director of Liver TransplantDepartment of GastroenterologyBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsAparna Goel, MDAssociate Clinical Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaContent based on an online CME program supported by independent educational grants from Gilead Sciences, Inc., and Ipsen Biopharmaceuticals, Inc​.To learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.

Sexnoveller Deluxe är tillbaka i gammal hederlig god form med såväl Natalie som Jonas vid mikrofonerna. Avsnittet utgörs av guldnovellerna: "Tjejfredag" samt "Smorda läppar" som båda såklart är helt jävla gyllene. Vill du stötta podden och ta del av exklusivt material som exempelvis ett par lite för explicita noveller och annat bus?Gå in https://www.patreon.com/sexnovellerdeluxePuss, kram och lite smek / Jonas & Natalie! Hosted on Acast. See acast.com/privacy for more information.

Dr. Ben Bikman opens this lecture with a comprehensive overview of fluoride's history in public health, highlighting its original role in preventing dental cavities. However, he shifts the focus to its lesser-known systemic effects, particularly on metabolic health.Ben emphasizes emerging evidence that chronic exposure to fluoride—from water, toothpaste, and other products—can disrupt fat cell function and insulin sensitivity, both key pillars of metabolic regulation.Dr. Bikman explains how fluoride interferes with fat cell development by inhibiting PPARγ, a key regulator of adipogenesis. While this may initially seem beneficial (fewer fat cells), it actually leads to hypertrophic fat cells that are more insulin resistant and pro-inflammatory. Though human data is limited, epidemiological studies suggest a link between high fluoride exposure and abdominal obesity.Fluoride's impact extends to insulin resistance and pancreatic function. Rodent studies show impaired glucose tolerance and reduced insulin production following fluoride exposure. Mechanistically, this is due to oxidative stress damaging mitochondria in beta cells, impairing both insulin release and glucose uptake. Human studies—though sparse—have shown similar trends in high-fluoride areas with improvements upon fluoride reduction.Ben also explores fluoride's effects on mitochondrial function, liver health, brain development, and fertility. Mitochondrial damage in fat and liver cells impairs energy production and fat metabolism, potentially leading to fatty liver disease. In the brain, fluoride may lower IQ and disrupt thyroid function—especially harmful during development. In fertility, fluoride is linked to lower sperm count and hormone disruption in animal models. Dr. Bikman concludes by recommending avoiding fluoride in drinking water while acknowledging its limited role in dental care.Show Notes/References:For complete show notes and references, we invite you to become a Ben Bikman Insider subscriber. As a subscriber, you'll enjoy real-time, livestream Metabolic Classroom access which includes live Q&A after the lecture with Ben, ad-free podcast episodes, show notes and references, online Office Hours access, Ben's Research Reviews Podcast, and a searchable archive that includes all Metabolic Classroom episodes and Research Reviews. Learn more: https://www.benbikman.com Hosted on Acast. See acast.com/privacy for more information.

Det har varit ellegala igen och alla tanter har gått bananas på nätet och skrivit elaka inlägg. D blir också en nördig tidsresa tillbaka i historien, vilka som förr var  världens sämsta föräldrar. Tess pappa berättar om sina hyss från 50 talet. Vi kan med lätthet konstatera att vissa saker var bättre förr då man tex slapp tjafsa om skärmtid.Puss och gla lyssning

Blekta bryn, face-tejp, våra måsten i necessären, glosset på ALLAS läppar, en facemist som förändrar allt - lyssna på vår maxade special om skönhet, smink och beauty! Emma Unckel är specialgäst. Hosted on Acast. See acast.com/privacy for more information.

This week's expert, Hepatologist and Key Opinion Leader Mazen Noureddin, joins Roger to discuss major advances in drug development over the past year. He covers a range of different drug classes, focusing on stages of development and the range of options within each class. First, Mazen discusses a tremendously exciting group of FGF-21 agents, specifically mentioning Akero Therapeutics's efruxifermin, 89bio's pegozafermin, and Boston Pharmaceuticals's efimosfermin. He points to efruxifermin's 96-week results to suggest that FGF-21s might be appropriate for a wide range of patients, the idea that the drug's duration of effect may make the idea of “induction therapy” less appropriate, and the exciting early data on cirrhosis patients. He also mentions pegozafermin's publication of data in the New England Journal of Medicine and efimosfermin's promising data based on monthly dosing. Next, Mazen provides some detail on the various incretin agonist options, why hepatologists are particularly excited about combinations that include a glucagon agent, and what kinds of results we might expect in upcoming trials. Finally, Mazen discusses other promising compounds in later-stage development, including the pan-PPAR lanifibranor and the FASN inhibitor denifenstat. He notes ongoing work on new classes and combination therapies. 

00:00:00 - Surf's Up: Season 6 Episode 4 Surfing the MASH Tsunami concludes its coverage of the AASLD Emerging Trends Conference on MASLD, MetALD and ALD. This week, the panelists focus on pivotal messages that attendees took away from the conference and what messages they would like to share with listeners. Our newsmaker, Fatty Liver Alliance and CEO Mike Betel, discusses the lessons he has taken from being invited to a far wider swath of conferences this year and shares the messages he delivers to these new audiences. Finally, our expert, hepatology research and key opinion leader Mazen Noureddin, discusses recent advances in drug development, focusing on agents in Phase 3 trials.00:04:24 - IntroductionHost Roger Green briefly describes this episode's three sections and one key lesson from each.00:06:03 - Roundtable: Highlights from the AASLD Emerging Trends Conference, Part 4This is the concluding portion of our Emerging Trends Conference Roundtable. The group focuses on key lessons they have learned and messages they would like listeners to take from this conversation.  The pivotal idea is that SLD is a spectrum running from MASLD through MetALD to ALD. Researchers and treaters will all do best in developing and implementing therapies and guidelines with this thought in mind. Aleksander Krag stresses this idea and notes that, with several different classes of drugs demonstrating positive impact, it will be an exciting decade ahead as we learn how to apply these drugs along the spectrum. Jenn Jones and Alex Lalos note the importance of identifying MetALD, although Jenn noted that it does not seem wise to conduct trials solely with MetALD patients at this time.  00:22:04 - Newsmaker: Mike Betel on the Increased Visibility of Patient AdvocatesThis week's newsmaker, Mike Betel, has experienced a significant increase in the number of conferences at which he is invited to speak or appear on a panel. This discussion centers around the reasons Mike believes this is happening and the message(s) he delivers. To Mike, his most important contribution lies in the amount of information he sends back from each event, many of which surpass 30% download rates (and some even hit 50%). He discusses his value in diabetes, endocrinology and obesity meetings, where he brings a "liver" perspective and co-education opportunity to these events. The entire experience has taught him about the need not to stigmatize patients and reinforced his belief in the importance of tailoring care to patients' needs and personalities. 00:49:28 - Expert: Mazen Noureddin on the Exciting MASLD Drug Development EnvironmentHepatologist and Key Opinion Leader Mazen Noureddin joins Roger to discuss major advances in drug development over the past year. He covers a range of different drug classes, focusing on stages of development and the range of options within each class. Specifically, he discusses the FGF-21 agents, the range of patients for whom they might be appropriate, how efruxifermin's 96-week results may make the idea of "induction therapy" less appropriate,  and the exciting early data on cirrhosis patients. He provides some detail on the various incretin agonist options, why hepatologists are particularly excited about combinations that include a glucagon agent, and what kinds of results we might expect in upcoming trials. He goes on to discuss the pan-PPAR lanifibranor, the FASN inhibitor denifenstat, and notes ongoing work on new classes and combination therapies. In general, he paints, I think, not a rosy, but an extremely optimistic picture of what the future will be for patients who need to be treated for fatty liver. 01:09:38 - Business Report Roger discusses the next Roundtable and provides some details on SurfingMASH's coverage of the upcoming EASL Congress.

In this podcast, expert faculty, Dr Stuart Gordon and Dr Nancy Reau, use an illustrative patient case to explore the roles of ALP and other biochemical markers in PBC management, and explain what to expect from treatment. Topics covered include: How baseline ALP can affect ALP normalization after second-line treatment with elafibranor and seladelparPotential outcomes if ALP normalization cannot be achievedThe importance of managing fatigue, pruritus, and sleep disturbances independently of the biochemical responsePresenters:Stuart C. Gordon, MDProfessor of MedicineWayne State University School of MedicineDirector, Division of HepatologyHenry Ford HealthDetroit, MichiganNancy Reau, MDProfessor of MedicineRichard B. Capps Chair of HepatologyChief, Section of HepatologyAssociate Director, Solid Organ TransplantationRush University Medical CenterChicago, IllinoisTo learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.  

In this podcast, expert faculty, Dr Stuart Gordon and Dr Nancy Reau discuss an illustrative patient case to demonstrate how they individualize primary biliary cholangitis (PBC) therapy for patients ​with cirrhosis. Topics covered include:AASLD guideline recommendations for second-line therapy for PBCConsiderations when using newer agents for second-line treatment of PBC in patients with cirrhosis: elafibranor and seladelparPresenters:Stuart C. Gordon, MD Professor of MedicineWayne State University School of MedicineDirector, Division of HepatologyHenry Ford HealthDetroit, MichiganNancy Reau, MD Professor of MedicineRichard B. Capps Chair of HepatologyChief, Section of HepatologyAssociate Director, Solid Organ TransplantationRush University Medical CenterChicago, IllinoisTo learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.

How do you decide when to move from first-line to second-line treatment for primary biliary cholangitis (PBC)? In this podcast, listen as experts Alan Bonder, MD, AGAF, and Aparna Goel, MD, discuss this question and more, including:How and when to measure treatment responseEvidence-based goals of therapyConsiderations for second-line treatmentNew agents for second-line treatment: PPAR agonistsPresenters:Alan Bonder, MD, AGAFAssociate Professor of MedicineMedical Director of Liver TransplantDepartment of GastroenterologyBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsAparna Goel, MDAssociate Clinical Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaContent based on an online CME program supported by independent educational grants from Gilead Sciences, Inc., and Ipsen Biopharmaceuticals, Inc​.To learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.Supported by educational grants from Gilead Sciences, Inc. and Ipsen Biopharmaceuticals, Inc

In this podcast, listen as experts Alan Bonder, MD, AGAF, and Aparna Goel, MD, discuss how they assess the symptoms of primary biliary cholangitis (PBC) and explore how new therapeutic agents may help alleviate symptom burden. Topics include:Strategies and tools for assessing pruritusNonpharmacologic and pharmacologic management of pruritusSecond-line agents and their impact on pruritusInvestigational treatments for pruritusPresenters:Alan Bonder, MD, AGAFAssociate Professor of MedicineMedical Director of Liver TransplantDepartment of GastroenterologyBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsAparna Goel, MDAssociate Clinical Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaContent based on an online CME program supported by independent educational grants from Gilead Sciences, Inc., and Ipsen Biopharmaceuticals, Inc​.To learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.

In this podcast, Sonal Kumar, MD, MPH, meets with patient advocate Maria Morais to discuss actionable steps that healthcare providers can incorporate into the care of people with primary biliary cholangitis (PBC). Listen as they discuss:The chronic nature of PBCGoing beyond biochemical markers to assess and address symptoms such as fatigue and pruritusThe importance of referral to patient support groupsPresenters:Sonal Kumar, MD, MPHAssistant Professor of MedicineDirector, General Gastroenterology and HepatologyWeill Cornell Medical CollegeNew York, New YorkMaria G. Morais, RNVP Patient AdvocacyCanadian PBC SocietyToronto, CanadaTo learn more, see the program Hear Me: Patient Perspectives on PBC

In this episode, Christopher L. Bowlus, MD, discusses recent advances in the management of primary biliary cholangitis (PBC), including:Treatment goalsUse of PPAR agonists for the treatment of PBCClinical trial results for elafibranor (ELATIVE), seladelpar (RESPONSE), and bezafibrate (BEZURSO)Presenter:Christopher L. Bowlus, MDLena Valente Professor and ChiefDivision of Gastroenterology and HepatologyUniversity of California Davis School of MedicineSacramento, CaliforniaLink to full program: https://bit.ly/41tvSDuGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Christopher L. Bowlus, MD, discusses recent advances in the management of primary biliary cholangitis (PBC), including:Treatment goalsUse of PPAR agonists for the treatment of PBCClinical trial results for elafibranor (ELATIVE), seladelpar (RESPONSE), and bezafibrate (BEZURSO)Presenter:Christopher L. Bowlus, MDLena Valente Professor and ChiefDivision of Gastroenterology and HepatologyUniversity of California Davis School of MedicineSacramento, CaliforniaLink to full program: https://bit.ly/41tvSDuGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/pbc-target-practice-normalization-is-the-new-norm/29110/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/does-your-patient-have-pbc/29108/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/pbc-is-risky-business/29109/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/initiating-second-line-therapy-what-when-and-then-what/29111/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/dont-forget-theres-a-sleepy-patient-behind-those-numbers/29112/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/dont-forget-theres-an-itchy-patient-behind-those-numbers/29113/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-the-treatment-of-pbc-part-1/29114/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-the-treatment-of-pbc-part-2/29115/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

Chris Duffin sits down with expert Anthony Castor to dive into the controversial world of nicotine and its effects on our brain and body. We'll explore how nicotine impacts neurotransmitters like dopamine, acetylcholine, norepinephrine, serotonin, and glutamate—shedding light on its roles in mood regulation, cognitive enhancement, fat loss, and even immune support. Together, Chris and Anthony will discuss the benefits and risks of nicotine use, comparing different delivery methods like gum, patches, and inhalers, and emphasizing the importance of moderation. They'll also delve into the historical context of nicotine, its pharmacokinetics, and its potential for aiding conditions like Alzheimer's, Parkinson's, and autoimmune diseases. Additionally, we'll hear about cutting-edge treatments in neural therapy and the synergy between nicotine and other cognitive enhancers. So, whether you're curious about the scientific intricacies or practical applications of nicotine, stay tuned for an engaging and informative discussion on harnessing the power of this complex compound for resilience and peak performance.   Anthony Castor is a distinguished chemist and researcher, renowned for his work on the effects of alkaloids on the human nervous system. Inspired by the early 19th-century discoveries of Wilhelm Heinrich Posselt and Carl Ludwig Reinman, who first isolated nicotine, Anthony has dedicated his career to examining its profound impact on body chemistry. With a keen focus on how nicotine binds to nicotinic acetylcholine receptors, Anthony's research has advanced our understanding of this powerful alkaloid, positioning him as a leading figure in the field of neurochemistry. His work continues to shed light on the complexities of naturally occurring compounds like nicotine, caffeine, and morphine, all of which share the commonality of containing nitrogen. This episode of the ARCHITECT of RESILIENCE podcast is available on Apple, Spotify & YouTube, and is sponsored by  @naboso_technology : The Foundation of Movement.

11 sätt att uppdatera din beautylook i höst! Vilken väljer du? Hosted on Acast. See acast.com/privacy for more information.

Biden och Trump igen. Hur kunde det bli så här? Live på Parkteatern i Stockholm 4 juli 2024. Lyssna på alla avsnitt i Sveriges Radio Play. Förutsatt att Joe Biden inte hoppar av kommer presidentvalet 2024 att stå mellan två historiskt impopulära kandidater i ett djupt polariserat land.I detta avsnitt utforskar vi hur Demokraterna kunde utse en 80-plussare till kandidat och sedan bli förvånade när han verkade märkt av sin ålder.Och hur det kommer sig att Republikanerna kunde sluta upp bakom Donald Trump efter att först ha förkastat honom för hans roll i stormningen av kongressen 2021?Avsnittet spelades in på Parkteaterns scen i Stockholm torsdag 4 juli 2024.Medverkande: Ginna Lindberg och Roger Wilson, Sveriges Radios USA-korrespondenter.Programledare: Sara StenholmProducent: Viktor MattssonTekniker: Christer Tjernell

BUFFALO, NY- July 10, 2024 – A new #research paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 12, entitled, “Aging exacerbates oxidative stress and liver fibrosis in an animal model of Down Syndrome.” Down Syndrome (DS) is a common genetic disorder characterized by an extra copy of chromosome 21, leading to dysregulation of various metabolic pathways. Oxidative stress in DS is associated with neurodevelopmental defects, neuronal dysfunction, and a dementia onset resembling Alzheimer's disease. Additionally, chronic oxidative stress contributes to cardiovascular diseases and certain cancers prevalent in DS individuals. In this new study, researchers Sebastiano Giallongo, Jessica Ferrigno, Rosario Caltabiano, Giuseppe Broggi, Amer M. Alanazi, Alfio Distefano, Emanuela Tropea, Antonella Tramutola, Marzia Perluigi, Giovanni Li Volti, Eugenio Barone, and Ignazio Alberto Barbagallo from the University of Catania, King Saud University, and Sapienza University of Rome investigated the impact of aging on oxidative stress and liver fibrosis using a DS murine model (Ts2Cje mice). “Our results show that DS mice show increased liver oxidative stress and impaired antioxidant defenses, as evidenced by reduced glutathione levels and increased lipid peroxidation.” DS liver exhibited an altered inflammatory response and mitochondrial fitness as the researchers showed by assaying the expression of HMOX1, CLPP, and the heat shock proteins Hsp90 and Hsp60. DS liver also displayed dysregulated lipid metabolism, indicated by altered expression of PPARα, PPARγ, FATP5, and CTP2. Consistently, these changes might contribute to non-alcoholic fatty liver disease development, a condition characterized by liver fat accumulation. Consistently, histological analysis of DS liver revealed increased fibrosis and steatosis, as showed by Col1a1 increased expression, indicative of potential progression to liver cirrhosis. Therefore, their findings suggest an increased risk of liver pathologies in DS individuals, particularly when combined with the higher prevalence of obesity and metabolic dysfunctions in DS patients. “These results shed a light on the liver's role in DS-associated pathologies and suggest potential therapeutic strategies targeting oxidative stress and lipid metabolism to prevent or mitigate liver-related complications in DS individuals.” DOI - https://doi.org/10.18632/aging.205970 Corresponding author - Giovanni Li Volti - livolti@unict.it Video short - https://www.youtube.com/watch?v=8GlAruy0xfk Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205970 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, Down Syndrome, oxidative stress, liver About Aging-US The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population. The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Check out Nascentmc.com for medical writing assistance. visit learnAMAstyle.com for free downloads on medical writing and editing Adbry for Atopic Dermatitis The FDA has approved tralokinumab-ldrm (Adbry) as a 300 mg single-dose autoinjector for moderate-to-severe atopic dermatitis (AD) in adults, offering a more convenient delivery method. Adbry, which inhibits IL-13, was previously approved for adults in December 2021 and for pediatric patients aged 12 and older in December 2023. The approval was granted to LEO Pharma Inc.  Augtyro for NTRK Tumors The FDA has approved repotrectinib (Augtyro) for treating solid tumors with NTRK gene fusions in patients aged 12 and older, based on Phase 1/2 trials showing significant response rates in both TKI-naïve and previously treated patients. The approval was granted to Bristol Myers Squibb, with additional clinical data required to confirm safety and efficacy. Donanemab for Alzheimer's FDA advisors unanimously recommended the approval of donanemab for Alzheimer's disease, emphasizing its efficacy in slowing early-stage disease and manageable risks. Donanemab, targeting amyloid plaques, offers potential advantages over Leqembi with monthly infusions. The FDA decision is expected soon. Iqirvo for Primary Biliary Cholangitis The FDA granted accelerated approval to elafibranor (Iqirvo) for primary biliary cholangitis (PBC) to be used with ursodeoxycholic acid or as monotherapy. Elafibranor targets PPAR-α and PPAR-δ, with Phase 2 trials showing significant biochemical responses. The approval was granted to GENFIT and Ipsen.  Retevmo in Thyroid Cancer The FDA granted full approval to selpercatinib (Retevmo) for advanced or metastatic RET fusion–positive thyroid cancer in patients aged 2 years and older, based on the LIBRETTO-001 trial showing high response rates. The approval was granted to Eli Lilly and Company. OTC Continuous Glucose Monitors The FDA approved Abbott Laboratories' continuous glucose monitoring systems, Libre Rio and Lingo, for over-the-counter use. Libre Rio is for Type 2 diabetes patients not on insulin, while Lingo targets non-diabetic consumers for health improvement. These systems provide real-time glucose monitoring via a smartphone app. Check out Nascentmc.com for medical writing assistance.visit learnAMAstyle.com for free downloads on medical writing and editing  

A new study entitled, “The Efficacy of Palmitoylethanolamide (Levagen+) on the Incidence and Symptoms of Upper Respiratory Tract Infection-A Double Blind, Randomised, Placebo-Controlled Trial” aimed to evaluate the effectiveness of a signaling lipid called Palmitoylethanolamide (PEA) in reducing the occurrence, duration, and severity of upper respiratory tract infections(URTIs). The results showed that participants who took PEA experienced fewer URTI episodes and had reduced symptoms compared to those who took a placebo, suggesting that PEA may be a safe and effective treatment option for URTIs. Palmitoylethanolamide (PEA) is a lipid compound that belongs to the N-acylethanolamine (NAE) family and has similar properties to endocannabinoids. In the context of cold and flu infections, PEA is suggested to regulate interleukins and inhibit mast cell production, thereby reducing inflammation. PEA activates NF-κB pathways through peroxisome proliferator-activated receptors (PPAR), particularly PPAR-α, and concentration-dependent mechanisms to decrease NLRP3 and inflammasome activation, ultimately leading to a decrease in the expression of cytokines and alleviation of upper respiratory tract infection symptoms. It is worth noting that the natural levels of PEA in the body and the use of PEA supplements have been found to be ineffective in producing significant clinical results due to poor absorption, resulting in low levels of PEA in the bloodstream. However, when PEA is combined with dispersion technology, such as Levagen+, the absorption of PEA is greatly improved, leading to higher concentrations in the bloodstream, which may enable a therapeutic effect. This study was conducted over a period of 12 weeks. It was a double-blind, randomized, placebo-controlled trial, where participants were divided into two groups: an active group receiving 300 mg of Levagen+ PEA twice a day and a placebo group receiving maltodextrin. The purpose of the study was to investigate the efficacy of Levagen+ PEA compared to the placebo in terms of the incidence, severity, and duration of upper respiratory tract infections (URTI).   During the study, 87 participants out of the total enrolled experienced at least one URTI, resulting in a total of 103 URTI episodes. The group receiving Levagen+ PEA reported significantly fewer URTI episodes (39) compared to the placebo group (64), and a lower number of participants who fell sick at least once during the study (32 vs. 55) when compared to the placebo group. Participants in the Levagen+ PEA group reported a significantly lower severity score for scratchy throat and cough. Overall, compliance with the study was high for both groups in terms of capsule consumption. The findings of the study indicate that individuals in the Levagen+ PEA group had a significantly lower number of upper respiratory tract infection (URTI) episodes compared to the placebo group. The study suggests that Levagen+ PEA could be a viable treatment for preventing upper respiratory tract infections (URTIs) and alleviating symptoms of cold and flu. The findings indicate that Levagen+ PEA is safe and effective in reducing the frequency of URTI episodes and relieving scratchy throats and coughing in individuals with URTI symptoms. I use PEA Luteolin Select from Moss Nutrition, which contains 300 mg of Levagen+ PEA and 50 mg of the flavonoid luteolin per capsule. PEA and luteolin have been shown to work synergistically in COVID-19-related illnesses such as Long COVID. I have patients take 1 capsule twice a day with meals of PEA Luteolin Select during COVID-19, cold, and flu season for prevention and then increase to 2 capsules three times a day when they feel like they're coming down with something. Hedberg Institute Members can download my latest upper respiratory tract infection protocols by logging in. Click here to learn more about the Hedberg Institute Membership.

References General and Comparative Endocrinology,2018-06-01, Volume 262, Pages 27-35 Pisendel JG 1735.Violin Concerto in D major, JunP I.5. https://youtu.be/dvwhXXvFiNg?si=YfS2waKLC5WHy0En --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support

During the 2023 American Association for the Study of Liver Diseases conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-δ agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.In this episode, Kris V. Kowdley MD, FAASLD, FACP, FACG, discusses topline results from several of these studies and more, including: A combination of 3 studies—HEROES, COBALT, and COBALT EC—that evaluated the real-world effectiveness and safety of second-line therapy in PBC where OCA was added to the treatment regimen of people with PBC with an incomplete response to ursodeoxycholic acid Lessons learned from a long-term outcomes study of people with PBCResults from 2 phase II studies of obeticholic acid plus bezafibrate in people with PBC who did not respond to or were intolerant of ursodeoxycholic acidPresenter:Kris V. Kowdley MD, FAASLD, FACP, FACGProfessor, Elson S. Floyd College of MedicineWashington State UniversityDirector, Liver Institute NorthwestSeattle, Washington      Link to reviews of other PBC studies from AASLD 2023: https://bit.ly/3RvXXEI